The Usher Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Usher Syndrome market dynamics.
DelveInsight’s “Usher Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Usher Syndrome, historical and forecasted epidemiology as well as the Usher Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover more about therapies set to grab major Usher Syndrome market share @ Usher Syndrome Market Forecast
Some of the key facts of the Usher Syndrome Market Report:
The Usher Syndrome market size was valued ~USD 77 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In December 2024, Italy-based AAVantgarde Bio, a clinical-stage biotech company focused on two proprietary Adeno-Associated Viral (AAV) vector platforms for delivering large genes, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead candidate, AAVB-081, for treating retinitis pigmentosa associated with Usher Syndrome Type 1B (USH1B).
In June 2024, Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for KYV-101. This autologous, fully human anti-CD19 CAR T-cell therapy is being developed for the treatment of stiff-person syndrome (SPS) as part of the company’s KYSA-8 clinical trial.
In 2023, the US had the highest number of prevalent Usher Syndrome cases among the 7MM, with approximately 21,000 cases. This number is projected to rise during the forecast period.
Among the EU4 and the UK, Germany had the highest number of prevalent Usher Syndrome cases in 2023, whereas Spain had the lowest.
Estimates indicate that in the US, type 2 Usher Syndrome was the most common, representing over 60% of all cases in 2023.
Key Usher Syndrome Therapies: Nacuity Pharmaceuticals, Laboratoires Théa, Sanofi, ProQR Therapeutics, Neurotech Pharmaceuticals, and others
Key Usher Syndrome Companies: NPI-001, Ultevursen, Oligonucleotide, NT-501, QR-421a, and others
The Usher Syndrome epidemiology, based on the specific age analyzed that Usher Syndrome are more prominent in Children compared to Adults
Usher Syndrome Overview
Usher syndrome is a rare genetic disorder primarily characterized by deafness due to an impaired ability of the inner ear and auditory nerves to transmit sensory (sound) input to the brain (sensorineural hearing loss) accompanied by retinitis pigmentosa (RP), a disorder that affects the retina and causes progressive loss of vision. Testing for hearing, balance, and vision and crucial inquiries about the patient’s medical history, are necessary to diagnose Usher syndrome.
Request a sample for the Usher Syndrome Market Report
https://www.delveinsight.com/sample-request/usher-syndrome-market
Usher Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Usher Syndrome Epidemiology Segmentation:
The Usher Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Usher Syndrome
Prevalent Cases of Usher Syndrome by severity
Gender-specific Prevalence of Usher Syndrome
Diagnosed Cases of Episodic and Chronic Usher Syndrome
Download the report to understand which factors are driving Usher Syndrome epidemiology trends @ Usher Syndrome epidemiology insights
Usher Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Usher Syndrome market or expected to get launched during the study period. The analysis covers Usher Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Usher Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Usher Syndrome Therapies and Key Companies
NPI-001: Nacuity Pharmaceuticals
Ultevursen: Laboratoires Théa
Oligonucleotide: ProQR Therapeutics
NT-501: Neurotech Pharmaceuticals
QR-421a: Nacuity Pharmaceuticals
To know more about Usher Syndrome treatment, visit @ Usher Syndrome Medications
Usher Syndrome Market Strengths
Usher syndrome is a frequently used modality for cancer treatment. As a result, a huge population suffers from Usher syndrome, which presents a huge market to any new entrant
The diagnosis of the disorder is easy with a clear clinical presentation, which helps in identifying the disease
Usher Syndrome Market Opportunities
Advances in radiation delivery technology, such as intensity-modulated radiation therapy, can help minimize radiation-induced skin toxicity in certain tumor types, such as breast cancer
There is great interest in improving the understanding of the mechanisms of dermal injury to ameliorate the dermatologic effects of radiation therapy, but prospective data to guide intervention are currently limited
Scope of the Usher Syndrome Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Usher Syndrome Therapeutic Assessment: Usher Syndrome current marketed and Usher Syndrome emerging therapies
Usher Syndrome Market Dynamics: Usher Syndrome market drivers and barriers
Usher Syndrome Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Usher Syndrome Unmet Needs, KOL’s views, Analyst’s views, Usher Syndrome Market Access and Reimbursement
Download the report to understand which factors are driving Usher Syndrome treatment trends @ Usher Syndrome treatment landscape
Table of Contents
1. Usher Syndrome Market Report Introduction
2. Executive Summary for Usher Syndrome
3. SWOT analysis of Usher Syndrome
4. Usher Syndrome Patient Share (%) Overview at a Glance
5. Usher Syndrome Market Overview at a Glance
6. Usher Syndrome Disease Background and Overview
7. Usher Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Usher Syndrome
9. Usher Syndrome Current Treatment and Medical Practices
10. Usher Syndrome Unmet Needs
11. Usher Syndrome Emerging Therapies
12. Usher Syndrome Market Outlook
13. Country-Wise Usher Syndrome Market Analysis (2020–2034)
14. Usher Syndrome Market Access and Reimbursement of Therapies
15. Usher Syndrome Market drivers
16. Usher Syndrome Market barriers
17. Usher Syndrome Appendix
18. Usher Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: 14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
